Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. In a lawsuit filed Thursday in a New ...

April 24 (Reuters) - Germany's Merck KGaA (MRCG.DE), opens new tab said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics (SWTX.O), opens new tab for about $3.5 ...

Halozyme Therapeutics (NASDAQ:HALO) on Thursday announced a lawsuit against Merck (NYSE:MRK) over allegations that an injectable version of the New Jersey-based pharma giant’s blockbuster cancer ...

Merck & Company (MRK) warns investors that it expects a $200 million hit from tariffs. Hasbro (HAS) stock is soaring after reporting a first quarter earnings beat. Comcast (CMCSA) stock sinks ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment Keytruda, alleging the pharmaceutical giant violated its intellectual ...

Halozyme Therapeutics is suing Merck for patent infringement. The San Diego biotechnology company said Thursday it believes a proposed form of Merck's cancer medicine Keytruda uses a formulation ...

Davis, chairman and chief executive officer, Merck. "We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave ...

Merck & Co. cut its 2025 earnings outlook, partly to account for recently imposed tariffs that it projects will total $200 million. The projection comes in light of the tariffs implemented so ...

Merck said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the U.S. and China. The estimate doesn’t account for the possibility that ...

Merck, while steadfast in its manufacturing push that aligns with the administration’s focus, is no different as it prepares for challenges ahead. While the company reaffirmed its full-year ...

Announcing better-than-expected financials for Q1 2025 on Thursday, Merck (NYSE:MRK) lowered its full-year outlook for earnings to account for various headwinds, including a $200M impact related ...

FILE- This May 1, 2018, file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, Nj – In its fourth quarter report, Merck, the giant pharmaceutical company with multiple ...